Need for an improved submission process for listing drugs for reimbursement in Canadian provinces.
BACKGROUND
To have a drug listed in a province's formulary, manufacturers must submit an application providing data required by the provincial rules and guidelines. The procedures for the scientific evaluation of drugs considered for listing for reimbursement in five provinces have been examined previously.


OBJECTIVE
The present study investigates the clarity of the same five provinces' rules and guidelines about effectiveness and cost data that should be included in listing submissions from the perspective of the pharmaceutical company.


METHODS
The manufacturers of five recently introduced drugs selected by the investigators received questionnaires asking about the departments within their companies that are responsible for the submission, the data required by each of the five provinces and the clarity of each province's requirements for submission. Each company was also asked similar questions about its own submission experience with its drug. Investigators visited each manufacturer to review the questionnaires and answer questions.


RESULTS
The manufacturers perceived the rules and guidelines on effectiveness and economic data of several provinces as being neither clear nor consistent. Consequently, information that companies submit in their attempts at compliance with the rules and guidelines varies substantially.


CONCLUSIONS
The manufacturers' perceptions of the information required by the provinces on effectiveness and cost information were inconsistent. Previous work indicated that the provinces make significant decisions about listings based on inadequate information resulting in a scientifically flawed system that contributes to considerable inequality in access to new drugs between provinces. The findings of the present work reinforce this conclusion.
West
Roy
R
Division of Community Health, Faculty of Medicine, School of Pharmacy, Memorial University of Newfoundland, St John's. roywest@mun.ca
Borden
E Keith
EK
Collet
Jean-Paul
JP
Rawson
Nigel S B
NS
Tonks
Robert S
RS
D002170:Canada; D003362:Cost-Benefit Analysis; D016527:Drug Costs; D004345:Drug Industry; D005569:Formularies as Topic / Q000592:standards*; D007349:Insurance, Health, Reimbursement / Q000331:legislation & jurisprudence / Q000592:standards*; D013219:State Government